Pieter Spee

Title: Pieter Spee: Innovator in KIR-Binding Agents

Introduction

Pieter Spee is a notable inventor based in Allerød, Denmark. He has made significant contributions to the field of immunology, particularly in the development of KIR-binding agents. With a total of 4 patents to his name, his work focuses on enhancing natural killer (NK) cell-mediated cytotoxicity.

Latest Patents

One of Pieter Spee's latest patents involves KIR-binding agents and methods of use thereof. This invention relates to agents and methods capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signaling without diminishing the binding of KIR to HLA-C. The patent describes how the transduction of negative signaling via KIR, upon binding to its HLA class I ligand, can lead to a conformational reorientation of KIR molecules. This reorientation allows for interactions between adjacent KIRs, resulting in accelerated clustering. The methods and agents, including monoclonal antibodies, aim to reduce KIR-mediated inhibition of NK cell cytotoxicity while preserving HLA-binding.

Career Highlights

Pieter Spee has worked with prominent companies in the biotechnology sector, including Novo Nordisk A/S and Innate Pharma S.A.S. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.

Collaborations

Pieter has collaborated with notable professionals in his field, including Stefan Zahn and Søren Berg Padkær. These collaborations have further enriched his research and development efforts.

Conclusion

Pieter Spee's innovative work in KIR-binding agents showcases his commitment to advancing immunological therapies. His contributions are significant in enhancing NK cell functionality, which may lead to improved treatments for various diseases.